# Genetic–Epigenetic Interplay in Epilepsy: Pathways, Biomarkers, and Epigenome-Targeted Therapies

## TL;DR

This review explores how genetic and epigenetic factors interact in epilepsy, highlighting new therapeutic strategies targeting the epigenome.

## Contribution

The paper provides a comprehensive synthesis of genetic-epigenetic interactions in epilepsy and their therapeutic implications.

## Key findings

- Epigenetic mechanisms like DNA methylation and histone modifications interact with genetic factors in epilepsy.
- Environmental influences can modify gene expression through epigenetic dysregulation, contributing to epilepsy.
- Epigenome-targeted therapies, such as HDAC inhibitors and CRISPR/dCas9, show promise for precision treatment.

## Abstract

Epilepsy is a heterogeneous neurological disorder with a strong genetic basis, yet recent evidence underscores the critical role of epigenetic mechanisms in its pathogenesis. This review synthesizes current knowledge on how chromatin remodeling, histone modifications, DNA methylation, and transcriptional regulation intersect with classical channelopathies and signaling pathways. We emphasize how epigenetic dysregulation contributes to neuronal excitability and network plasticity, particularly through interactions with mTOR, PI3K-AKT, and GABAergic signaling cascades. The convergence of genetic mutations and epigenetic modifications creates a dynamic landscape in which environmental factors can modify gene expression and contribute to the development of epilepsy. Emerging therapeutic strategies—including epigenetic drugs (HDAC inhibitors, DNMT inhibitors), CRISPR/dCas9-based epigenome editing, and multi-omics approaches—offer promising avenues for precision medicine. This review provides a comprehensive synthesis of genetic and epigenetic mechanisms in epilepsy, examining how these layers interact to produce disease phenotypes and discussing the therapeutic implications of this multilayered regulation.